Prenetics went public via a SPAC merger with Artisan Acquisition in a $1.25bn deal.

Prenetics, a company specializing in genomic and diagnostic testing, went public via a SPAC merger with Artisan Acquisition, a special purpose acquisition company, in a $1.25bn deal. The transaction included a $120m PIPE from Aspex, PAG, Lippo, Dragonstone and Xen Capital. "This announcement is a significant milestone for Prenetics and for Hong Kong entrepreneurs. Our goal is to decentralize healthcare by bringing it closer to millions of patients globally. I am humbled and honoured by Adrian's trust in us, and we look forward to continuing to work closely across his extensive business network to deliver on the massive potential which exists to disrupt the healthcare market. With a strong existing business, an exciting product pipeline, and a clear M&A acquisition strategy for USA geographical expansion, we have first-mover advantage and are well-positioned for our next chapter of growth," Danny Yeung, Prenetics CEO and Co-Founder.